Functional validation of these rare fusions by RNA-NGS showed that 4 of 5 intergenic-breakpoint fusions were validated, with 2 intergenic-FGFR1 fusions in lung cancer accounting for 50% of FGFR1-positive lung cases. This evidence concerns the gene FGFR1 and lung cancer.